For more information please contact:
Head of Healthcare Investment Banking
Michael Margolis, R.Ph.
Warren Dunnavant II
Head of Equity
Senior Vice President
On August 16, 2013, Retrophin, Inc. (OTCQB: RTRX) ("Retrophin" or the "Company") announced a PIPE financing which resulted in gross proceeds of approximately $25 million. The Company intends to use the aggregate net proceeds of the transaction to pursue its recently announced exclusivity agreement with a major pharmaceutical company for the right to negotiate a royalty-bearing U.S. license for a product to be developed for the treatment of Autism and Schizophrenia, as well as for the continued advancement of its pipeline.
ROTH Capital Partners, LLC acted as co-lead placement agent to Retrophin in this transaction.
In addition to the transaction highlighted above, ROTH Capital Partners, LLC acted as sole placement agent for Retrophin in its $9.1 million private placement in February 2013.
Retrophin is a pharmaceutical company focused on the discovery and development of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently no viable patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin's lead compound, RE-021, is scheduled to begin enrollment in a potentially pivotal Phase 2 clinical trial for FSGS during 2013. (Source: Company Press Release, 8/16/2013)
ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. and Hong Kong. For more information on ROTH, please visit